Evidence map›Paper›PMID 29671116›Full record

ArticleGlycoconjugate journal2018

MPDU1 regulates CEACAM1 and cell adhesion in vitro and in vivo.

Daniel C Bennett, Aurelie Cazet, Jon Charest, Joseph N Contessa

Open access · greenAbstract read
In one paragraph

Article in Glycoconjugate journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Daniel C BennettDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06510, USA.
Aurelie CazetDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06510, USA.
Jon CharestDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06510, USA.
Joseph N ContessaDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06510, USA. joseph.contessa@yale.edu.
Yale University · US

Funding

Targeting N-linked Glycosylation to Enhance Radiation TherapyR01CA172391 · NCI · YALE UNIVERSITY · PI CONTESSA, JOSEPH N · 2014 to 2018
$2.0M
RESEARCH TRAINING: RADIATION THERAPY, BIOLOGY, PHYSICST32CA009259 · NCI · YALE UNIVERSITY · PI GLAZER, PETER M · 1985 to 2009
$1.4M
Foundation for the National Institutes of Health 1R01CA172391NCI NIH HHS R01 CA172391NCI NIH HHS T32 CA009259
6 · The paper itself

Abstract

N-linked glycosylation (NLG) is a co-translational modification that is essential for the folding, stability, and trafficking of transmembrane (TM) and secretory glycoproteins. Efficient NLG requires the stepwise synthesis and en bloc transfer of a 14-sugar carbohydrate known as a lipid-linked oligosaccharide (LLO). The genetics of LLO biosynthesis have been established in yeast and Chinese hamster systems, but human models of LLO biosynthesis are lacking. In this study we report that Kato III human gastric cancer cells represent a model of deficient LLO synthesis, possessing a homozygous deletion of the LLO biosynthesis factor, MPDU1. Kato III cells lacking MPDU1 have all the hallmarks of a glycosylation-deficient cell line, including altered sensitivity to lectins and the formation of truncated LLOs. Analysis of transcription using an expression microarray and protein levels using a proteome antibody array reveal changes in the expression of several membrane proteins, including the metalloprotease ADAM-15 and the cell adhesion molecule CEACAM1. Surprisingly, the restoration of MPDU1 expression in Kato III cells demonstrated a clear phenotype of increased cell-cell adhesion, a finding that was confirmed in vivo through analysis of tumor xenografts. These experiments also confirmed that protein levels of CEACAM-1, which functions in cell adhesion, is dependent on LLO biosynthesis in vivo. Kato III cells and the MPDU1-rescued Kato IIIM cells therefore provide a novel model to examine the consequences of defective LLO biosynthesis both in vitro and in vivo.

Indexed as

Gene Expression RegulationAntigens, CDCell AdhesionCell Adhesion MoleculesCell Line, TumorGlycolipidsGlycosylationHumansAntigens, CDCD66 antigensCell Adhesion MoleculesGlycolipidsLLOMPDU1N-linked glycosylationTumor

Identifiers

PMID29671116
PMCPMC6013378
OpenAlexW2801177893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.